Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III PXT3003 versus placebo in Charcot-Marie-Tooth disease type 1A
2020-004805-30Phase 3Terminated
- Sponsor
- Pharnext
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Charcot-Marie-Tooth disease type 1A (CMT1A) comparing PXT3003 with Placebo (2 arms). Primary endpoint: Change in modified Overall Neuropathy Limitation Scale. Started Feb 2021; status: terminated.
02
Drugs
PXT 3003
03
Conditions
Charcot-Marie-Tooth disease type 1A (CMT1A)
Beyond the preview
Go deeper on 2020-004805-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004805-30.